Preliminary evaluation and in vitro cytotoxicity studies of [ 131 I]I-trastuzumab in HER2 expressing ovarian cancer cells
Journal of Radioanalytical and Nuclear Chemistry(2022)
摘要
As trastuzumab is known to target the human epidermal growth factor receptor type (HER2), the potential of [ 131 I]I-trastuzumab as a radioimmunotherapy agent was evaluated in vitro and in vivo for HER2-overexpressing ovarian cancer cells (SKOV-3). [ 131 I]I-trastuzumab showed promising in vitro properties and high tumor uptake in SKOV-3 xenografts. Its cellular toxicity was dose- and time-dependent, and it retained in the SKOV-3 cells in the G2/M phase of cell cycle. The mode of cell death was predominantly by apoptosis. These results demonstrate the potential of [ 131 I]I-trastuzumab for further therapeutic evaluation in HER2-overexpressing ovarian cancers.
更多查看译文
关键词
Iodine-131, Trastuzumab, Ovarian tumors, HER2 overexpression, Cell cycle, Apoptosis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要